Compare Sirius XM Holdings Inc (SIRI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs 10X Genomics Inc — how do they compare? Sirius XM Holdings Inc trades at $26.51 (market cap $8.87B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Sirius XM Holdings Inc and 10X Genomics Inc are close in size by market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and 10X Genomics Inc for 91 Days on average.
| SIRI | TXG | |
|---|---|---|
Market Cap | $8.87B | $10.07B |
Volume | 4,324,672 | 5,657,286 |
Sector | Media | Health |
52-Week High | $32.59 | $97.74 |
52-Week Low | $19.92 | $11.48 |
Typical Hold Time | 102 Days | 91 Days |
Enterprise Value | $18.16B | $9.59B |
Dividend Yield | 4.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings (SIRI) trades at $26.33, up 1.46% with mixed technical signals showing neutral momentum. The stock presents attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, though recent earnings have been inconsistent with two misses in the last four quarters. Strong cash flow generation of $1.9B in 2025 supports the company's dividend payments and strategic initiatives, including recent YouTube advertising partnerships and technology leadership appointments.
SIRI offers value investment potential with upside to the $34.43 consensus price target, representing 31% potential return. However, investors face risks from inconsistent earnings performance and competitive pressures in the audio entertainment space. The company's improving balance sheet with debt-to-asset ratio declining to 35.63% provides financial stability, while institutional accumulation signals confidence in the turnaround story.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
